Results 161 to 170 of about 34,135 (204)

Efficacy and safety of PARP inhibitors in advanced or recurrent endometrial cancer: a systematic review and meta-analysis. [PDF]

Front Immunol
Zhang H, Yan G, Yan J, Zeng X.
europepmc   +1 more source

Characterization of exceptional responders with long-term PARP inhibitor therapy in recurrent ovarian cancer: an analysis of 23 patients from Charité. [PDF]

Arch Gynecol Obstet
Glajzer J, Sehouli J, Woopen H, Braicu EI, Baum J, Grabowski JP.   +5 more
europepmc   +1 more source

Long-Term Survival With Olaparib Maintenance Therapy in Metastatic Pancreatic Carcinoma of a Patient Harboring Germline BRIP1 and ATM Mutations. [PDF]

Case Rep Oncol Med
Birhiray RE, Birhiray MN, Ranger SL, Flanders VL.   +3 more
europepmc   +1 more source

Evaluating carboplatin and PARP inhibitor combination efficacy using high-grade serous carcinoma spheroids and organoids. [PDF]

Cancer Biol Ther
Tomas EJ, Davis J, Ramos Valdes Y, Shepherd TG.   +3 more
europepmc   +1 more source

Clinicopathological and functional evaluation of replication protein A in epithelial ovarian cancers: A target validation study. [PDF]

Transl Oncol
Algethami M, Sheha A, Singhania N, Alqahtani S, Shoqafi A, Tosun Ç, Spicer J, Toss MS, Alblihy A, Lashen A, Jeyapalan JN, Mongan NP, Rakha EA, Madhusudan S.   +13 more
europepmc   +1 more source

Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment. [PDF]

Elife
Zhang Y, Xu M, Yuan J, Hu Z, Jiang J, Sun Y, Huang J, Wang Y, Wang B, Shen J, Long M, Fan Y, Montone KT, Tanyi J, Kim SH, Tavana O, Vonderheide RH, Chan HM, Domchek S, Zhang L, Hu X.   +20 more
europepmc   +1 more source

Hepatobiliary adverse drug reactions during treatment with olaparib: an analysis of data from the EudraVigilance reporting system. [PDF]

Front Drug Saf Regul
Velişcu EM, Cagnotta C, Sullo MG, Anatriello A, Salvo F, Scavone C.   +5 more
europepmc   +1 more source

Maintenance therapy after first-line therapy for ovarian cancer: Quantitative effectiveness. [PDF]

CA Cancer J Clin
Campos SM, DiSilvestro J, Blank SV.
europepmc   +1 more source

Assessing PARP trapping dynamics in ovarian cancer using a CRISPR-engineered FRET biosensor. [PDF]

Cell Rep Methods
Marks D, Garcia E, Kumar S, Tyson K, Koch C, Ivanov AP, Edel JB, Mirza HB, Flanagan W, Dunsby C, French PMW, McNeish IA.   +11 more
europepmc   +1 more source